Omeros reported the publication of results from a Phase 2 trial investigating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery
SEATTLE, WA, USA | June 29, 2011 | Omeros Corporation (NASDAQ:OMER - News) today reported the publication of results from a Phase 2 trial investigating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery. OMS103HP is Omeros' product candidate being developed for use during arthroscopic procedures and is designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. The article titled "Novel Drug, OMS103HP, Reduces Pain and Improves Joint Motion and Function over 90 Days following Arthroscopic Meniscectomy" is currently available on line at www.arthroscopyjournal.org and will appear in the August 2011 print edition of Arthroscopy: The Journal of Arthroscopic and Related Surgery.